10% holder buying at Resverlogix (T:RVX)

Shenzhen Hepalink Pharmaceutical Co., a 10% Holder, acquired 4,479,793 Common Shares at a price of $3.00 and 2,239,897 Warrants exercisable at $3.21 for a period of three years on a direct ownership basis through a prospectus or prospectus exempt offering on March 29th, 2019. This represents a $13,439,379 investment into the company's shares and an account share holdings change of 5.8%.

Resverlogix is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Resverlogix Corp is Canada-based clinical-stage biotechnology company. The Company is developing apabetalone (RVX-208), a molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease. Apabetalone is being studied in a Phase III trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).